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Abstract
Background: Long-term term survival in patients with pancreatic neuroendocrine tumors has been reported, even
in patients with metastatic disease. Metastases to the spleen are extremely rare, but have been reported from a
number of primary malignancies, such as breast cancer, lung cancer, melanoma and ovarian cancer. This is the first
report of a splenic metastasis from a primary pancreatic neuroendocrine tumor.
Case presentation: The patient presented as a 53 years old white male with anemia and fatigue. Physical
examination revealed a left upper quadrant fullness and computed tomography showed a 24 cm left upper
quadrant mass with multiple liver metastases, splenomegaly and a 1 cm mass in the spleen. Resection of the
primary pancreatic tumor (T4N0M1) was accompanied by gastrectomy, splenectomy and resection of adherent
bowel. The spleen contained a metastatic lesion 1.0 cm in diameter, consistent with a primary
neuroendocrine tumor of the pancreas. This operation was followed 8 months later, by delayed resection of
liver metastases. The patient receives monthly administration of somatostatin long-acting analogue and has
undergone several ablations of liver lesions with percutaneous radiofrequency ablation as well as a second
liver resection. The patient is alive seven years after initial presentation, with no evidence of disease on
imaging studies.
Conclusions: This is the first report of a splenic metastasis from a primary pancreatic neuroendocrine tumor.
The patient initially presented with synchronous multiple liver metastases and a single splenic metastasis.
After resection of the primary tumor and spleen, the patient has undergone aggressive cytoreductive surgery/
ablation of liver lesions and somatostatin therapy with resulting long-term survival.
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Background
Neuroendocrine tumors occur throughout the body, and
have a variety of presentations and clinical characteris-
tics. Pancreatic neuroendocrine tumors (pNETs) are par-
ticularly rare, representing only 1-2% of all pancreatic
neoplasms, but the treatment of these lesions continues
to evolve with improving results. NETs are classified sep-
arately from carcinoid tumors, in part based on location
[1–3]. The clinical presentation of NETs primarily de-
pends on whether they are functional or non-functional,
and if they are functional, depending on what hormone is
being produced [2]. Compared with NETs from other ori-
gins, patients with NETs of gastrointestinal origin are
more likely to have metastases at the time of presentation
[4]. The prognosis of patients with these tumors depends
on a number of factors, but liver metastases are very com-
mon, being present at the time of presentation in up to
65% of patients, and are often associated with a poorer
prognosis [2]. Biologic factors related to the tumor (Ki-67
index and mitotic index) have also been shown to be im-
portant and are incorporated into the 2010 WHO grading
scheme for these lesions [2, 3, 5]. Prolonged survival, even
in the presence of liver metastases has been reported with
aggressive treatment [1, 4].
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Metastases to the spleen have been reported from a
variety of primary tumors. They remain extremely rare,
no matter what the primary lesion is. In a meta-analysis
of 713 patients with splenic metastases, Lam reported
23% from breast cancer primaries, 20% from lung, 9%
from colon/rectum, 9% from ovary and the rest from the
stomach, prostate, and other organs [6]. The reported
incidence may be increasing due to improvements in im-
aging technology, but they are usually found in patients
with multiple visceral metastatic sites in the terminal
stage [7]. Solitary splenic metastases are very unusual.
The pathogenesis of metastases to the spleen is usually
considered to be of arterial origin, but may be from
tumor thrombi in the splenic vein [8]. The reasons for
the rarity of splenic metastases rare are not understood.
Mechanical factors may limit implantation of cells (angle
of the splenic artery and contraction of the organ).
There are also micro-environmental factors (absence of
afferent lymphatics and local anti-tumor activity) which
inhibit the growth of metastatic cells [6, 7].
We report the case of a patient who initially presented
with a pNET with synchronous liver metastases and a
single metastasis to the spleen. This is the first report of
a metastasis to the spleen from a pNET.
Case presentation
The patient presented as a 53 years old white male
with anemia and fatigue. Previous history included no
medications, distal left lower extremity venous thrombo-
phlebitis 2 months prior, status post laparoscopic gastric
Roux-en-Y bypass (for obesity and diabetes mellitus which
had been untreated and resolved postoperatively) three
years prior to presentation and a left ulnar nerve decom-
pression nine years prior. Physical examination revealed
no palpable lymphadenopathy, a fullness in the left upper
quadrant and fecal occult blood positive stool. Laboratory
studies showed a serum hemoglobin of 6 mg/dl. Com-
puted tomography (CT) scan of the abdomen showed a
24 cm left upper quadrant mass with multiple liver lesions,
splenomegaly and a 1 cm mass in the spleen (Fig. 1). A
laparoscopic liver biopsy was performed and histopath-
ology was initially reported as hepatocellular carcinoma
versus hepatoid carcinoma. One month later, serum
hemoglobin was 4.4 mg/dl and gross melena was seen.
Blood transfusions did not resolve the anemia. Serum
albumin was decreased to 1.7 g/dl.
The patient underwent gastrectomy, splenectomy, dis-
tal pancreatectomy and resection of small bowel and a
portion of colon that were adherent to the tumor mass.
At the end of surgery, there was no gross tumor
remaining except for the previously identified liver me-
tastases. Pathology showed a tumor that originated in
the pancreas with direct extension to the small bowel,
colon, and stomach. The resected specimen weighed
3500 g and the spleen measured 14x7x10cm (Fig. 2). On
cut section, the spleen contained a 1.0 cm lesion consist-
ent with a metastasis, which was then confirmed to be a
metastatic lesion on histopathologic evaluation (Fig. 3).
The final pathology report showed a pNET, well differ-
entiated, stage T4N0M1 with 0/13 lymph nodes contain-
ing tumor. The lesion in the spleen was located near the
edge of the spleen, but there was no direct invasion by
the tumor mass (Figs. 2 and 3) grossly or histologically.
Examination of the splenic vein showed no evidence of
thrombosis with only minimal invasion by the tumor
histologically. There were three mitoses per 50 high
power fields, and Ki-67 < 1%. Perineural and lymphovascu-
lar invasion was seen. Immunostains for chromogranin A
Fig. 1 Preoperative computed tomography scan of the abdomen
shows a 24 cm mass in the left upper quadrant between the spleen
and liver, and a single metastatic lesion (1 cm) in the spleen (arrows)
Fig. 2 Gross pathology image of the cut surface of the spleen and
tumor showing a 1.0 cm metastasis (arrow), corresponding to the
lesion seen on the computed tomography scan
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and synaptophysin are positive (Fig. 4). Immunostains for
CD56, OCGH1E5, AFP, glucagon, insulin, somatostatin,
pancreatic polypeptide, alpha 1-anti trypsin, alpha 1 anti-
chymotrypsin and lipase are negative. Blood chemistry
studies showed that this was a non-functional tumor.
The patient was discharged home ten days after surgery
and returned two weeks later with intra-abdominal sepsis
treated with drainage of fluid and antibiotics. Diabetes mel-
litus recurred in this patient after pancreatic resection. Som-
atostatin administration, long-acting release 20 mg/month
was started. Approximately 8 months after the resection of
the primary lesion, repeat imaging studies (CT scan, mag-
netic resonance imaging) and an octreotide nucleotide scan
showed no lesions outside the liver. Left lateral segmentect-
omy was performed with simultaneous resection of multiple
hepatic nodules throughout the liver. All lesions were con-
sistent with metastases from the previously resected pri-
mary tumor on histopathologic examination.
The patient was discharged without complications,
and continued monthly somatostatin therapy as well as
periodic CT scans to evaluate recurrence. About one year
after liver resection, a new lesion appeared in the liver
which was treated with percutaneous radiofrequency abla-
tion (RFA). The patient did well until 14 months later
when multiple liver lesions appeared. A second liver resec-
tion was completed, including resection of nine nodules
(<1 cm size) and RFA of two central liver lesions. It
was felt that all lesions visible were treated at that time.
Seventeen months later, another liver lesion appeared
which was centrally located and treated with percutan-
eous RFA. An octreotide scan showed no evidence of
disease. About 20 months later another central area in
the liver was treated with percutaneous RFA.
The patient is now seven-years status post resection of the
primary lesion, treated with monthly administration of som-
atostatin long acting release 20 mg IM, and followed with
periodic CT scans of the liver. Diabetes mellitus persists and
is treated with insulin. At seven years, there is no evidence
of residual disease in the abdomen, or within the paren-
chyma of the liver. He remains asymptomatic and is doing
well. The patient’s clinical history is summarized in the
Table 1, prepared in accordance with CARE guidelines [9].
Fig. 3 Histopathology of the spleen lesion, with an appearance
similar to the histopathology of the primary lesion in the pancreas.
The metastatic lesion extends close to, but not through the splenic
capsule and is separate from the adjacent tumor. (Hematoxylin and
eosin stain, 15X)
Fig. 4 a Histopathological findings revealed that the tumor was composed of cells with round nuclei arranged in sheets or rosettes (Hematoxylin
and eosin stain × 100). b The tumor cells were weakly positive for synaptophysin by immunohistochemical staining (×100), c The chromogranin A
(×100), and MIB 1 index was about 10% (d) In this case, CD56 and other immunohistochemical stains were negative except for SSTR-2 (x100)
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Discussion
Neuroendocrine tumors are rare, but their reported
incidence has increased over the last decades, which is
attributed to improved diagnostic modalities and sur-
veillance [4, 7]. In one study, the incidence from 1974
to 2004 more than doubled, from 1.4 new cases per
million to 3.0 [10]. Gastrointestinal neuroendocrine
tumors have a higher likelihood of presenting with
metastases, which are present in about 50–65% of pa-
tients at the time of diagnosis. With the availability of
new treatment modalities, long-term survival is re-
ported, even in patients who present with metastatic
disease. A recent review showed that the combination
of long-acting somatostatin analogue therapy with ag-
gressive cytoreductive surgery can result in long-term
survival in some patients with metastatic NETs origin-
ating in the gastrointestinal tract [4].
In a series of 46 patients with pNETs, 48% presented
with loco-regional disease and 52% presented with me-
tastases [11]. All patients without metastases underwent
resection, and the authors report a three-year survival of
86% with a median 42 months follow-up. Patients with
metastatic disease were treated with a variety of modal-
ities including resection, ablation, chemoembolization
and others, and had a three-year survival of 70%. The
authors credit their use of a multidisciplinary multi-
modal approach. An aggressive approach to these lesions
was also reported by Touzios et al [1], who categorized
the treatment of 60 patients with pNET into three
groups: no treatment, resection, and transarterial che-
moembolization. Five-year survival was 25% in the no
treatment group, 72% for the resection group and 50%
for the transarterial treated group. They also found poor
outcomes in patients with >50% involvement of the liver.
The impact of lymph node involvement on survival in
patients with pNET was studied by Krampitz and col-
leagues [12]. They found that disease-related survival de-
creased as a function of the number of lymph nodes
involved. However, in patients with liver metastases and
lymph node metastases, the major determinant of survival
is the presence of liver metastases. The probability of sur-
vival at 10 years is 30% in this series. In a large series of
patients with non-functional pNETs, tumor size and nodal
status were not associated with survival, while tumor
grade and systemic metastases were associated [10].
Somatostatin receptor scintigraphy is an important
modality in the evaluation of these patients, and peptide
receptor radionuclide therapy has shown promising results
in the therapy of these lesions [13]. Transplantation has
been used in select patients with results similar to trans-
plantation performed for hepatocellular carcinoma [14].
These authors advise waiting for stabilization of liver dis-
ease prior to proceeding to transplantation. However,
transplantation is generally not considered as a first-line
therapy for metastatic neuroendocrine tumors [4].
The presence of splenic metastases is usually reported
in the context of a pre-terminal event with multiple vis-
ceral metastases. In this patient, it is of interest that the
single spleen metastasis was found at the initial presen-
tation. The origin of the splenic metastasis is the subject
of some speculation. In the spleen, it is believed that
reticulo-endothelial create an unfavorable environment
for the growth and survival of tumor cells [6, 7, 15].
Splenic metastases are believed to originate from the
splenic artery, splenic vein, or lymphatics [8]. However,
there are few lymphatic ducts to the spleen, and most
metastases are considered of hematogenous origin [16].
Marymont et al demonstrated that splenic metastases
are seen in the venous sinusoids and /or red pulp, sup-
porting a hematogenous origin [17]. The splenic artery
would appear to be the most common origin of splenic
metastases although this suggests systemic circulation of
tumor cells, and metastases in other organs may be ex-
pected, making solitary splenic metastases less likely. In
patients with pNET, liver metastases from the portal
vein are extremely common. In the present patient, al-
though histologic evaluation of the portal vein showed
no evidence of portal vein thrombus, the huge tumor
mass and minimal invasion of the splenic vein seen on
histologic evaluation, may have affected portal vein out-
flow, leading to congestion of the splenic vein and possibly
resulting in development of a splenic metastasis [18].
Table 1 Timeline of care
Prior History
• -9 years: Left ulnar nerve decompression
• -3 years: Roux-en-Y gastric bypass for obesity with resolution of previously
untreated Type 2 Diabetes Mellitus
Diagnosis and Interventions
• Anemia, fatigue, left upper quadrant fullness on physical examination,
serum hemoglobin 7 mg/dl
• CT scan showed a 24 cm left upper quadrant mass with multiple liver
metastases and a single 1 cm spleen metastasis
• Laparoscopic liver biopsy: read as hepatocellular carcinoma vs.
hepatoid carcinoma
• +1 month: Serum hemoglobin 4.0 g/dl, surgery for completion
gastrectomy, splenectomy, small bowel resection, colon resection, and
distal pancreatectomy, complicated by intra-abdominal sepsis treated
non-operatively
Follow-up and outcomes
• +8 months: left lateral segmentectomy of the liver, resection of
multiple liver nodules
• +20 months: solitary liver lesion treated with percutaneous RFA
• +35 months: multiple liver lesions, open resection with intraoperative
RFA
• +52 months: Percutaneous RFA of central liver lesion
• +77 months: Negative octreotide scan, percutaneous RFA of central
liver lesion
• +84 months: No evidence of disease, monthly administration of long
acting release somatostatin (20 mg) and diabetes mellitus (treated with
insulin)
CT Computed tomography, RFA radiofrequency ablation
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In patients with late appearance of splenic lesions,
treatment may be futile but splenectomy may benefit pa-
tients who experience significant pain due to splenomegaly.
Isolated splenic metastases were extremely rare in a series
of 92 splenic metastases, representing just 4% of the lesions
[6]. In that series, 26% of the spleens weighed more than
200 g. It is estimated that only about 100 cases of isolated
splenic metastases have been reported [19], from diverse
primary tumors. Splenectomy for isolated metastases can
result in long term survival [7]. It has been suggested that
splenic metastases may result from the growth of early
blood-borne tumor cells, after a latent period [7]. Lap-
aroscopic splenectomy is a reasonable surgical option
in a patient with an isolated splenic metastasis.
Despite an extensive review of the literature including
multiple databases (keywords “spleen”, “metastases”,
“neuroendocrine”), there are no reports of patients with
metastases to the spleen from pNETs. In one review of
unusual locations for metastases from neuroendocrine
tumors, there were no lesions metastatic to the spleen
[20]. Metastases to the spleen have been reported for
bronchial carcinoid tumors [21, 22]. The spleen has been
reported to be involved with neuroendocrine tumors of
the pancreas, including a tumor thrombus in the splenic
vein without a mass in the spleen [23] and as a splenic
mass from direct extension and gastric varices [24]. The
rarity of splenic metastases is not entirely surprising, since
pNETs and splenic metastases are both rare entities.
Conclusions
This is the first report of a splenic metastasis from a
primary pancreatic neuroendocrine tumor. There are a
number of interesting features in the present patient’s
clinical history. The spleen metastasis in this patient was
solitary and found at initial presentation, rather than as a
pre-terminal event. This patient had no lymph node metas-
tases at initial presentation which is unusual in the presence
of liver metastases. This patient has undergone aggressive
cytoreductive treatment and monthly administration of
long-acting somatostatin analogue that have likely contrib-
uted to the continued survival of this patient.
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